Additional Articles by the Authors
Jeffrey T. Guptill, MD, MA, MHS; M. Chris Runken, PharmD; Michael Eaddy, PharmD, PhD;
Orsolya Lunacsek, PhD; Rupali M. Fuldeore, MS
Enhanced Understanding and Management of Rare Diseases Can Reduce Costs, Improve Clinical Outcomes
James T. Kenney, RPh, MBA
Todd Williamson, PhD, MSc; Wendy Y. Cheng, MPhil, MPH; Nora McCormick, MSc; Francis Vekeman, MA
Jordan S. Orange, MD, PhD; Matt Johnson, BA; Barb Lennert, RN, BSN, MAOM; Katarzyna Shields,
PharmD, MBA, BCOP, BCPS; Michael Eaddy, PharmD, PhD
A Useful Tool for Evaluating Disease Severity and Alternative Treatments Efficacy
Gary Branning, MBA
Important Insights from Real-World Treatment Patterns and Outcomes for Varicose Veins Management
Generic Imatinib: Can It Provide Significant Cost Relief for Patients?
Assessing the Value of Patient-Reported Outcomes
We Need More Research on True Value-Based Benefit Design that Will Improve Outcomes and Control Costs
Benefit Management Considerations for BPH Medications: Single Agent or Combination Therapy?
Results 1 - 9 of 9